There is a flourishing biosimilar medicine industry in India focussed on the supply of affordable biologics to the domestic market. Regulators in India have already approved over 50 biosimilar drugs. Companies such as Dr Reddy’s, Biocon and Intas Biopharmaceuticals are internationally recognised brands and play a leading role within this sector. The success that Indian biosimilar companies have experienced within their home territory is leading them to consider tactics for tapping into global markets in North America, Europe and Japan.